Insulin NovoNordisk NovoRapid FlexPen
Insulin NovoNordisk NovoRapid FlexPen is a medicine authorised by Swissmedic under authorisation number 55712. The authorisation holder is Novo Nordisk Pharma AG. The medicinal product code is Biotechnological medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 08 December 2000 and the authorisation is valid without a time limit. ATC code A10AB05 places the medicine in the group Drugs used in diabetes.
| Authorisation number | 55712 |
|---|---|
| Name | Insulin NovoNordisk NovoRapid FlexPen |
| Full name | Insulin NovoNordisk NovoRapid FlexPen, Injektionslösung |
| Authorisation holder | Novo Nordisk Pharma AG |
| Medicinal product code | Biotechnological medicines |
| Dispensing category | B · Prescription only |
| ATC code | A10AB05 |
| First authorisation | 08 December 2000 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Insulin NovoNordisk NovoRapid FlexPen, Injektionslösung | B | 08 December 2000 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 5 x 3 | ml | A10AB05 | 07.06.1. | B |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Insulin NovoNordisk NovoRapid FlexPen authorised in Switzerland?
Yes. Insulin NovoNordisk NovoRapid FlexPen is authorised by Swissmedic under authorisation number 55712, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Insulin NovoNordisk NovoRapid FlexPen have?
Insulin NovoNordisk NovoRapid FlexPen is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Insulin NovoNordisk NovoRapid FlexPen?
The authorisation holder is Novo Nordisk Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.